Cocrystal Pharma Files 8-K
Ticker: COCP · Form: 8-K · Filed: May 1, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | May 1, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing
TL;DR
Cocrystal Pharma filed an 8-K on May 1st. Standard disclosure.
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on May 1, 2024, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as BIOZONE PHARMACEUTICALS, INC. and International Surf Resorts, Inc., is incorporated in Delaware and headquartered in Bothell, WA.
Why It Matters
This filing provides official updates and disclosures from Cocrystal Pharma, Inc. to the SEC, which can impact investor understanding of the company's status.
Risk Assessment
Risk Level: low — This is a routine filing with no immediate material financial events or significant changes disclosed.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- BIOZONE PHARMACEUTICALS, INC. (company) — Former company name
- International Surf Resorts, Inc. (company) — Former company name
- May 1, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report for Cocrystal Pharma, Inc., covering Regulation FD Disclosure and Financial Statements and Exhibits.
When was this 8-K filed?
The 8-K filing was made on May 1, 2024.
What are the former names of Cocrystal Pharma, Inc.?
Cocrystal Pharma, Inc. was formerly known as BIOZONE PHARMACEUTICALS, INC. and International Surf Resorts, Inc.
Where is Cocrystal Pharma, Inc. headquartered?
Cocrystal Pharma, Inc. is headquartered at 19805 N. Creek Parkway, Bothell, WA 98011.
In which state is Cocrystal Pharma, Inc. incorporated?
Cocrystal Pharma, Inc. is incorporated in Delaware.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-05-01 08:00:42
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001493152-24-017354.txt ( ) — 247KB
- cocp-20240501.xsd (EX-101.SCH) — 3KB
- cocp-20240501_lab.xml (EX-101.LAB) — 33KB
- cocp-20240501_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 1, 2024 Cocrystal Pharma, Inc. By: /s/James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer